Interview with Dr. Ahmed Sheriff on CRP apheresis for COVID-19 patients
ntv has broadcast an interview with Dr. Ahmed Sheriff about CRP apheresis for COVID-19 patients. Among other things, they talk about the lack of funding for medical devices in the Corona Pandemic.
ZDF reports on CRP apheresis as salvation for COVID-19 patients
ZDF has reported on CRP apheresis treatment for COVID-19 patients.
At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.
In the 2nd issue 2021 of Forum Sanitas an article about the dark side of CRP has been published.
The latest findings on the pathological action of CRP are summarized and the potential clinical applications of CRP apheresis in acute myocardial infarction, COVID-19, and other conditions are described.
Promising treatment success in patients with severe COVID-19 courses
Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.